FDA Approves Zycubo: First Treatment For Menkes Disease In Children

In a landmark decision announced on January 12, 2026, the FDA approved Zycubo, developed by SentyNL Therapeutics, as the first therapy for children suffering from Menkes disease. The condition, caused by a genetic defect that prevents proper copper absorption, leads to seizures, growth failure, and neurological decline. Children with the most common form of the disease rarely survive beyond three years.  

Zycubo works by delivering copper directly through subcutaneous injection, bypassing the defective absorption pathway. Clinical studies demonstrated significant survival benefits, particularly when treatment begins within the first four weeks of life. The FDA emphasized that this approval marks a critical step in addressing rare pediatric disorders and reflects ongoing collaboration with the rare disease community.  

Key Highlights  
FDA approves Zycubo (copper histidinate) injection for pediatric Menkes disease  
First-ever treatment option for this rare genetic disorder  
Therapy bypasses defective copper absorption via direct injection  
Clinical trials show improved survival when started early  
Approval underscores FDA’s commitment to rare disease drug development  

Final Takeaway  
Zycubo’s approval represents a breakthrough in rare disease treatment, offering families a new lifeline against Menkes disease. Early intervention with this therapy could transform outcomes for affected children, marking a pivotal advancement in pediatric medicine.  

Sources: FDA Press Release, Reuters, Los Angeles Issue